These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Angiogenesis-related molecular targets in esophageal cancer. Hong L; Li S; Han Y; Du J; Zhang H; Li J; Zhao Q; Wu K; Fan D Expert Opin Investig Drugs; 2011 May; 20(5):637-44. PubMed ID: 21443389 [TBL] [Abstract][Full Text] [Related]
3. Angiogenesis in esophageal and gastric cancer: a paradigm shift in treatment. Barzi A; Thara E Expert Opin Biol Ther; 2014 Sep; 14(9):1319-32. PubMed ID: 24881691 [TBL] [Abstract][Full Text] [Related]
8. The role of bevacizumab in colorectal cancer: understanding its benefits and limitations. Mulder K; Scarfe A; Chua N; Spratlin J Expert Opin Biol Ther; 2011 Mar; 11(3):405-13. PubMed ID: 21281258 [TBL] [Abstract][Full Text] [Related]
9. Clinical significance of VEGF-A, -C and -D expression in esophageal malignancies. Kleespies A; Bruns CJ; Jauch KW Onkologie; 2005 May; 28(5):281-8. PubMed ID: 15867486 [TBL] [Abstract][Full Text] [Related]
10. Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinoma. Cen P; Hofstetter WL; Correa AM; Wu TT; Lee JH; Ross WA; Davilla M; Swisher SG; Fukami N; Rashid A; Maru D; Ajani JA Cancer; 2008 Mar; 112(5):1020-7. PubMed ID: 18205187 [TBL] [Abstract][Full Text] [Related]
11. Targeting angiogenesis in head and neck cancer. Seiwert TY; Cohen EE Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442 [TBL] [Abstract][Full Text] [Related]
12. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab. Marty M; Pivot X Eur J Cancer; 2008 May; 44(7):912-20. PubMed ID: 18396037 [TBL] [Abstract][Full Text] [Related]
13. [Novel angiogenesis inhibitors for molecular target therapy of cancer]. Osada H; Kakeya H Nihon Rinsho; 2004 Jul; 62(7):1257-63. PubMed ID: 15283141 [TBL] [Abstract][Full Text] [Related]
14. Tumor vasculature: the Achilles' heel of cancer? Johannessen TC; Wagner M; Straume O; Bjerkvig R; Eikesdal HP Expert Opin Ther Targets; 2013 Jan; 17(1):7-20. PubMed ID: 23121690 [TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic strategies for cancer therapy (Review). Benouchan M; Colombo BM Int J Oncol; 2005 Aug; 27(2):563-71. PubMed ID: 16010440 [TBL] [Abstract][Full Text] [Related]
16. Bone marrow micrometastases and markers of angiogenesis in esophageal cancer. Spence GM; Graham AN; Mulholland K; Maxwell P; McCluggage WG; Sloan JM; McGuigan JA Ann Thorac Surg; 2004 Dec; 78(6):1944-9; discussion 1950. PubMed ID: 15561005 [TBL] [Abstract][Full Text] [Related]
17. Expression of angiostatic platelet factor-4var/CXCL4L1 counterbalances angiogenic impulses of vascular endothelial growth factor, interleukin-8/CXCL8, and stromal cell-derived factor 1/CXCL12 in esophageal and colorectal cancer. Verbeke H; De Hertogh G; Li S; Vandercappellen J; Noppen S; Schutyser E; El-Asrar AA; Opdenakker G; Van Damme J; Geboes K; Struyf S Hum Pathol; 2010 Jul; 41(7):990-1001. PubMed ID: 20334899 [TBL] [Abstract][Full Text] [Related]
18. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies. Leite de Oliveira R; Hamm A; Mazzone M Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050 [TBL] [Abstract][Full Text] [Related]
19. The Challenge of Developing New Therapies for Childhood Cancers. Balis FM Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032 [TBL] [Abstract][Full Text] [Related]
20. Development of new drug strategies in infrequent digestive tumors: esophageal, biliary tract, and anal cancers. Capdevila J; Ramos FJ; Macarulla T; Elez E; Ruiz-Echarri M; Perez-Garcia J; Tabernero J Curr Opin Oncol; 2009 Jul; 21(4):374-80. PubMed ID: 19412097 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]